Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 54
Filtrar
1.
Arch. Soc. Esp. Oftalmol ; 98(1): 2-10, ene. 2023. tab, ilus
Artigo em Espanhol | IBECS | ID: ibc-214329

RESUMO

Antecedentes y objetivo Evaluar el impacto económico en España derivado de la introducción del implante XEN®63 como alternativa quirúrgica en el manejo del glaucoma primario de ángulo abierto (GPAA) con o sin cataratas en pacientes refractarios. Materiales y métodos Se diseñó un análisis de impacto presupuestario para estimar los costes del tratamiento quirúrgico del GPAA desde la perspectiva del Sistema Nacional de Salud (SNS) español, en un horizonte temporal de1 año. Los comparadores considerados (trabeculectomía, esclerectomía profunda no perforante, válvula de Ahmed, iStent inject®, Preserflo® microshunt y XEN®45) se corresponden a los empleados en la práctica clínica pública española. Para el cálculo de la población diana, cuotas de mercado y uso de recursos en términos de visitas de seguimiento, procedimientos adicionales y complicaciones poscirugía, se emplearon datos de la literatura y se validaron con un panel de cuatro expertos. Los costes unitarios (€de2021) se obtuvieron de la base de datos ESALUD Resultados la inclusión de XEN®63 podría generar un ahorro de 2.569.737€ tras un año desde su introducción, derivado del ahorro en el coste del implante y del procedimiento (−423.120; −0,7%), de las visitas de seguimiento (−777.407€; −4,5%), de los procedimientos adicionales (−1.048.145€, −20,6%) y de las complicaciones poscirugía (−321.065€, −14,2%). Conclusiones La incorporación de XEN®63 en el arsenal quirúrgico para el tratamiento del GPAA refractario con y sin cataratas podría generar ahorros para el SNS (AU)


Background and objective To evaluate the economic impact in Spain derived from the introduction of the XEN®63 implant as a surgical alternative in the management of primary open angle glaucoma (POAG) with or without cataract in refractory patients. Materials and methods A budget impact analysis was designed to estimate the costs of surgical treatment of POAG from the perspective of the Spanish National Health System (NHS), over a time horizon of 1year. The comparators considered (trabeculectomy, deep non-perforating sclerectomy, Ahmed valve, iStent inject®, Preserflo® microshunt and XEN®45) correspond to those used in Spanish public clinical practice. For the calculation of the target population, market shares and resource use in terms of follow-up visits, additional procedures and post-surgery complications, data from the literature were used and validated with a panel of 4 experts. Unit costs (€2021) were obtained from the ESALUD database. Result The inclusion of XEN®63 could generate savings of €2,569,737 after one year since its introduction, derived from savings in the cost of the implant and procedure (−€423,120; −0.7%), follow-up visits (−€777,407; −4.5%), additional procedures (−1,048,145; −20.6%) and post-surgery complications (−€321,065; −14.2%). Conclusion The incorporation of XEN®63 in the surgical arsenal for the treatment of refractory POAG with and without cataracts could generate savings for the NHS (AU)


Assuntos
Humanos , Glaucoma de Ângulo Aberto/cirurgia , Custos de Cuidados de Saúde , Trabeculectomia/métodos , Glaucoma de Ângulo Aberto/economia , Extração de Catarata , Trabeculectomia/economia , Espanha
2.
Arch Soc Esp Oftalmol (Engl Ed) ; 98(1): 2-10, 2023 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-36427747

RESUMO

BACKGROUND AND OBJECTIVE: To evaluate the economic impact in Spain derived from the introduction of the XEN®63 implant as a surgical alternative in the management of primary open angle glaucoma (POAG) with or without cataract in refractory patients. MATERIALS AND METHODS: A budget impact analysis was designed to estimate the costs of surgical treatment of POAG from the perspective of the Spanish National Health System (NHS), over a time horizon of 1 year. The comparators considered (trabeculectomy, deep non-penetrating sclerectomy, Ahmed valve, iStent inject, Preserflo® microshunt and XEN®45) correspond to those used in Spanish public clinical practice. For the calculation of the target population, market shares and resource use in terms of follow-up visits, additional procedures and post-surgery complications, data from the literature were used and validated with a panel of 4 experts. Unit costs (€ 2021) were obtained from the ESALUD database. RESULTS: The inclusion of XEN®63 could generate savings of €2,569,737 after one year since its introduction, derived from savings in the cost of the implant and procedure (-€423,120; -0.7%), follow-up visits (-€777,407; -4.5%), additional procedures (-€1,048,145; -20.6%) and post-surgery complications (-€321,065; -14.2%). CONCLUSIONS: The incorporation of XEN63®in the surgical arsenal for the treatment of refractory POAG with and without cataracts could generate savings for the NHS.


Assuntos
Catarata , Glaucoma de Ângulo Aberto , Trabeculectomia , Humanos , Glaucoma de Ângulo Aberto/cirurgia , Espanha , Resultado do Tratamento , Catarata/complicações
17.
Arch. Soc. Esp. Oftalmol ; 90(10): 484-486, oct. 2015. ilus
Artigo em Espanhol | IBECS | ID: ibc-142748

RESUMO

CASO CLÍNICO: Una paciente de 60 años fue remitida para cirugía de catarata. En la exploración presentaba pigmento retroquerático en el ojo izquierdo (OI). La presión intraocular fue de 24 mmHg en el OI. El examen del fondo de ojo mostró una lesión marrón en el disco óptico izquierdo, con dispersión de pigmento en el vítreo adyacente, y se diagnosticó de síndrome de dispersión pigmentaria secundario a melanocitoma de nervio óptico. DISCUSIÓN: Aunque el melanocitoma es por lo general un tumor benigno y no progresivo, puede presentar complicaciones que den lugar a una importante pérdida de visión. Un paciente con melanocitoma del nervio óptico debe ser examinado periódicamente


CASE REPORT: A 60-year old patient was referred for cataract surgery. The examination showed retrokeratic pigment in the left eye, which had an intraocular pressure of 24 mmHg. The funduscopy showed a brown lesion on the left optic disk, with adjacent vitreous seeding of pigment. The patient was thus diagnosed with secondary pigment dispersion syndrome due to optic disk melanocytoma. DISCUSSION: Although melanocytoma is most commonly a benign, stationary tumor, it may present with major complications leading to significant visual loss. A patient with melanocytoma of the optic disk should be examined periodically


Assuntos
Idoso , Feminino , Humanos , Nervo Óptico/anormalidades , Nervo Óptico/patologia , Acuidade Visual , Retina/anormalidades , Retina/patologia , Retina , Doenças Retinianas/complicações , Doenças Retinianas/patologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...